Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega deal
The company lifted full-year net sales and expense guidance and outlined ten clinical readouts for the second half of 2026, including four registrational trials.
Incyte reported second quarter 2026 results on July 28, 2026 and updated its full-year guidance. The company said it is raising its full year 2026 total net sales guidance to $5,130 to $5,260 million, reflecting the impact of the agreement with CMS related to the Opzelura line extension, as well as continued performance of its Hematology and Oncology growth products including Niktimvo, Monjuvi/Minjuvi and Zynyz.1 It also raised full year 2026 operating expense guidance, with total GAAP R&D and SG&A guidance now $4,915 to $4,995 million and non-GAAP guidance at $4,625 to $4,695 million.1 That revision reflects the acquisition of Vega Therapeutics, including an IPR&D expense of approximately $1,270 million expected in the third quarter of 2026, plus $50 million of incremental ongoing R&D investment tied to latarcibart.1
On the pipeline side, Incyte said the registrational Phase 3 EXCALIBUR-ET2 study of INCA033989 in mutCALR positive ET patients resistant or intolerant to prior cytoreductive therapy was initiated in mid-2026.1 The company also discontinued further development of INCB160058 (JAK2V617F) following a review of available data, to prioritize its next-generation JAK2V617F pipeline.1 For latarcibart, acquired with Vega Therapeutics, Phase 1/2 multidose data presented at ISTH in July showed an 81% median reduction in annualized bleeding rate across all bleeding categories and VWD types with once-monthly subcutaneous dosing.1 The global Phase 3 VIVID-6 study is assessing once-monthly latarcibart as VWD bleeding prophylaxis, with topline data anticipated in early 2029.1
Regulatory updates included global submissions for Monjuvi/Minjuvi in newly diagnosed DLBCL accepted in the second quarter, with potential U.S. approval and launch anticipated in the first quarter of 2027,1 and an FDA-accepted NDA for povorcitinib in moderate to severe hidradenitis suppurativa, with potential approval and launch anticipated in late 2026 in the EU and the first quarter of 2027 in the U.S.1
On cash, cash, cash equivalents and marketable securities as of June 30, 2026 were $4.5 billion, compared to $3.6 billion as of December 31, 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.